![](https://investorshub.advfn.com/uicon/4754.png?cb=1706362874)
Tuesday, May 16, 2017 7:58:34 AM
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131123105
If USRM gets fast track, the stock will see $5-8 immediately since they were almost done with phase 3 when they applied. With RMAT they are allowed to use non-clinical data - meaning that they can use the results from outside the country. They could realistically commercialize within 3 months after fast track.
If USRM gets phase 4 approval, the stock will see $12-18 immediately because they will be able to schedule the heart procedure that very day in the clinics that are already located throughout the US and there are plans to open 10 more clinics which will also be able to handle the procedures.
These are not made up numbers and may actually seem conservative. Look at PPS spikes for cancer drugs as there is a plethora of information showing PPS after FDA approval. USRM is attempting to solve the number one cause of death with their product and there is no competition currently. The major difference between cancer drug approval and USRM stem cell therapy is that this therapy has little or no side effects. The cancer drugs all have a ton of side effects that might seem worse than the cancer.
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM